Empowering Life Science Partners with Real-World Evidence
Flatiron Health stands at the forefront of oncology real-world evidence, aiding life science partners in conducting critical health economics and outcomes research (HEOR) studies. These studies are particularly crucial in supporting Health Technology Assessments (HTA), essential for accelerating access to cancer treatments globally. With a track record of over 30 HTA submissions, Flatiron data has been recognized as a premier, comprehensive source of oncology data, contributing significantly to assessing comparative effectiveness.
Global Influence and Impact
Flatiron's influence extends across international borders, transforming cancer care and research in major oncology markets such as Japan, Germany, the United Kingdom, and the United States. By expanding its high-quality datasets beyond the US, Flatiron is enabling a global perspective to address pressing questions for patients worldwide. Noteworthy collaborations with HTA bodies like NICE are proving to be instrumental in bridging evidence gaps and informing HTA decisions, bringing real-world data to the forefront of oncology.
Pioneering Research Collaborations
Flatiron's commitment to high-impact research collaborations is evident in its work with esteemed life science partners and HTA bodies. Through innovative collaborations, Flatiron is exploring ways to fill evidence gaps and enhance HTA decision making, ultimately advancing market access for new oncology medicines. The success stories, like the approval of atezolizumab by NICE, underscore the power of comprehensive data packages that leverage Flatiron's reliable data sources.
Driving Market Access and HTA Use Cases
Flatiron's approach to evidence generation is bolstered by its cutting-edge platform, Flatiron Horizon. This platform seamlessly integrates real-world data, cutting-edge technology, proprietary curation methods, and expert insights, reinforcing Flatiron's position as a trusted partner for generating real-world evidence for value and market access decisions. The research insights and resources provided by Flatiron elevate discussions around critical aspects of Health Technology Assessment, offering guidance on transporting comparative effectiveness evidence and addressing key considerations in HTA processes.
Empowering Decision-Making with RWE Consortium
In response to the evolving landscape of oncology and the increasing importance of real-world evidence, Flatiron is spearheading the FLATIRON FORUM. This consortium, aimed at fostering collaboration with global life science companies, seeks to enhance decision-making processes by leveraging exemplar RWE and research methodologies. By facilitating better decision-making through robust evidence, Flatiron is dedicated to expediting patient access to cutting-edge oncology therapies, further cementing its commitment to advancing market access and HTA practices.